Skip to main content
Clinical Trials/NCT00674934
NCT00674934
Unknown
Phase 1

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.

GAAD Medical Research Institute Inc.1 site in 1 country5 target enrollmentMay 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
GAAD Medical Research Institute Inc.
Enrollment
5
Locations
1
Primary Endpoint
Treatment of MS
Last Updated
17 years ago

Overview

Brief Summary

Multiple sclerosis (abbreviated MS) is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. This study will investigate the use of far infrared radiation for MS control, management and treatment.

Detailed Description

MS a demyelinating disease, is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved. MS affects the areas of the brain and spinal cord known as the white matter. White matter cells carry signals between the grey matter areas, where the processing is done, and the rest of the body. More specifically, MS destroys oligodendrocytes which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath, which helps the neurons carry electrical signals. Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have MS.

Registry
clinicaltrials.gov
Start Date
May 2008
End Date
June 2010
Last Updated
17 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
GAAD Medical Research Institute Inc.

Eligibility Criteria

Inclusion Criteria

  • Patients with MS

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Treatment of MS

Time Frame: 2 years

Secondary Outcomes

  • Rehabilitation of MS Patients(2 Years)

Study Sites (1)

Loading locations...

Similar Trials